M. James Barrett

General Partner Emeritus & Strategic Adviser at New Enterprise Associates

M. James Barrett

M. James Barrett

General Partner Emeritus & Strategic Adviser at New Enterprise Associates

Overview
Career Highlights

Smithkline Clinical Laboratories
Genetic Therapy, Inc.
Life Technologies, Inc.

RelSci Relationships

6736

Number of Boards

39

Birthday

1943

Age

77

Number of Awards

1

Relationships
RelSci Relationships are individuals M. James Barrett likely has professional access to. A relationship does not necessarily indicate a personal connection.

General Partner, Washington DC at New Enterprise Associates

Relationship likelihood: Strong

Managing General Partner at New Enterprise Associates

Relationship likelihood: Strong

Investor at MindTickle, Inc.

Relationship likelihood: Strong

Co-Founder at Clovis Oncology, Inc.

Relationship likelihood: Strong

General Partner at New Enterprise Associates

Relationship likelihood: Strong

Co-Founder at Mereo BioPharma Group Plc

Relationship likelihood: Strong

Special Partner at New Enterprise Associates at GumGum, Inc.

Relationship likelihood: Strong

Managing General Partner at New Enterprise Associates

Relationship likelihood: Strong

Co-Founder at GlycoMimetics, Inc.

Relationship likelihood: Strong

Senior Vice President, Chief Financial Officer & Principal Accounting Officer at Madrigal Pharmaceuticals, Inc.

Relationship likelihood: Strong

Paths to M. James Barrett
Potential Connections via
Relationship Science
You
M. James Barrett
General Partner Emeritus & Strategic Adviser at New Enterprise Associates
Education
BS in Chemistry

Boston College is one of the nation's best and most selective universities, with U.S. News & World Report ranking Boston College 31st among national universities, and Forbes ranking it 26th in its 2012 America's Best Colleges listing. Boston College confers more than 4,000 degrees annually in more than 50 fields of study through eight schools and colleges. Faculty members are committed to both teaching and research having earned nearly $60 million in research grants in the last year alone. The University has made a major commitment to academic excellence. As part of its Strategic Plan, Boston College is in the process of adding 100 new faculty positions, expanding faculty and graduate research, increasing student financial aid to more than $128 million annually, and widening opportunities in key undergraduate programs, such as international study, internships and student formation. Boston College has experienced tremendous growth in recent years, including a 75 percent increase in undergraduate applications over the past decade, to more than 34,000 for the 2,250 seats in its freshman class. During the same period, an increase in voluntary giving from alumni has helped to move the University's endowment to approximately $1.9 billion. Boston College students have also earned more than 200 prestigious academic scholarships over the past decade, including 2 Rhodes Scholarships, 4 Marshalls, 9 Goldwaters and 162 Fulbright grants.

Ph.D. in Biochemistry

The University of Tennessee (also referred to as the University of Tennessee, Knoxville, UT Knoxville, UT, or UTK) is a public sun-grant and land-grant university headquartered at Knoxville, Tennessee, United States. Founded in 1794, two years before Tennessee entered the Union as the 16th state, it is the flagship institution of the statewide University of Tennessee system with nine undergraduate colleges and eleven graduate colleges and hosts almost 28,000 students from all 50 states and more than 100 foreign countries.

MBA

The SCU Leavey School of Business is a private academic institution at Santa Clara University. It is one of the professional schools of Santa Clara University. The School of Business was founded in 1923 and accredited by the Association to Advance Collegiate Schools of Business thirty years later. Located in the Silicon Valley.

Ph.D Biochemistry
Career History
General Partner Emeritus & Strategic Adviser
2001 - Current

New Enterprise Associates (NEA) focuses on investments in the technology and healthcare sectors. The firm's investment strategy spans all stages of a company's growth, from seeding innovations in emerging markets to funding early-stage companies in high-growth markets to fueling the growth of market leaders. NEA actively invests in emerging markets, with emphasis on India and China.NEA's investments in the healthcare sector focus on companies that address unmet or underserved clinical needs and that combine improved clinical outcomes with lower costs to the market. The firm targets three areas including biopharmaceuticals, medical devices and healthcare services. The firm has a history of partnering with companies that have pioneered transformative innovations in healthcare, such as balloon angioplasty and laparoscopic surgeryWithin the technology sector, NEA focuses on investments in the electronics, consumer technology, enterprise mobility, virtualization, tech-enabled services, SaaS and cloud computing industries.

Member of the Exempt Reporting Adviser
2000 - Current

NEA Management Co. is an investment advisor located in Timonium, Maryland.

Manager
Prior - 2015
Boards & Committees
Director
Prior - 2015
Independent Director
2014 - Prior

Cerecor, Inc. is a clinical stage biopharmaceutical company focuses in medical development. It involves in the discovery, manufacture and commercialization of prescription for neurological and psychiatric disorders. It products include CERC-301, CERC-501, CERC-611, and CERC-406. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher and Solomon H. Snyder on January 31, 2011 and is headquartered in Baltimore, MD.

Director
Prior - 2011

Peptimmune was founded in 2002 with technology from the laboratories of Dr. Jack Strominger, Higgins Professor of Biochemistry at Harvard University; and Dr. Hidde Ploegh, from the Whitehead Institute for Biomedical Research. Peptimmune has therapeutics in clinical development for the treatment of multiple sclerosis. Peptimmune's flagship program in multiple sclerosis features PI-2301, which has the opportunity to replace Copaxone® (Teva Pharmaceuticals), the world's leading first-line therapy for the treatment of MS.Peptimmune has broad expertise in MHC Class II molecules and their role in antigen presentation and modulation of immune responses. The Company exploits its proprietary DEEP Technology (Directed Expansion of Epitope Permutation) to design peptides and peptide mixtures for development as therapeutics, diagnostic kits, and as reagents for antibody generation. The Company is building a unique suite of expertise in the manufacture and control of peptide copolymer-based drug products.

Non-Profit Donations & Grants

Learn how non-profit organizations benefit from RelSci
$10K - $15K
2014

MARET IS A VIBRANT K-12, CO-EDUCATIONAL, INDEPENDENT SCHOOL IN WASHINGTON, DC. WE IGNITE OUR STUDENTS' POTENTIAL AND FOSTER THEIR ACADEMIC, ARTISTIC, AND ATHLETIC TALENTS.

$5,000 - $10K
2013

MARET IS A VIBRANT K-12, CO-EDUCATIONAL, INDEPENDENT SCHOOL IN WASHINGTON, DC. WE IGNITE OUR STUDENTS' POTENTIAL AND FOSTER THEIR ACADEMIC, ARTISTIC, AND ATHLETIC TALENTS.

Political Donations
$1,175
2012
$975
2011
$1,050
2010
Transactions
Details Hidden

ASN Technologies, Inc. purchases Senseonics, Inc. from HealthCare Ventures LLC, Abingworth LLP, Rho Ventures, New Enterprise Associates, Anthem Capital Management LLC, Roche Ventures

Details Hidden

Bristol-Myers Squibb Company purchases Cardioxyl Pharmaceuticals, Inc. from The Aurora Funds, Inc., New Enterprise Associates, Osage Partners LLC, OrbiMed Advisors Private Equity

Details Hidden

Senseonics, Inc. raised money in a private placement transaction

Investments
Details Hidden

Senseonics, Inc. develops transformative glucose monitoring products. It develops Senseonics continuous glucose monitoring system, an implantable continuous glucose monitoring system, which includes a miniaturized sensor and receiver that is inserted into the subcutaneous space under the skin to wirelessly transmit glucose levels to an external receiver. The company was founded by Michael James Barrett and Arthur E. Colvin in 1996 and is headquartered in Germantown, MD.

Details Hidden

NEA Management Co. is an investment advisor located in Timonium, Maryland.

Public Holdings
Restricted data only for RelSci Professional users.
Awards & Honors
Rank #78
2012
Forbes Magazine - The Midas List
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by M. James Barrett. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of M. James Barrett's profile does not indicate a business or promotional relationship of any kind between RelSci and M. James Barrett.